Tanezumab: Anti-NGF monoclonal antibody treatment of pain treatment of osteoarthritis

Drugs of the Future

Volumn 35, Issue 5, 2010, Pages 373-378

  Haddley, K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 911; MORPHINE; MORPHINE SULFATE; NAPROXEN; NERVE GROWTH FACTOR; OXYCODONE; PF 04383119; PLACEBO; RI 624; TANEZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALLODYNIA; ANALGESIA; ARTHRALGIA; ARTHRITIS; ARTICLE; BONE PAIN; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERESTHESIA; HYPERSENSITIVITY; LOW BACK PAIN; MUSCLE CRAMP; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; PAIN ASSESSMENT; PARESTHESIA; RESPIRATORY DISTRESS; SENSORY NERVE; TREATMENT OUTCOME;

EID: 77955461004     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.05.1508523     Document Type: Article

References (48)

1. Thoenen, H., Barde, Y.A., Davies, A.M., Johnson, J.E. Neurotrophic factors and neuronal death. Ciba Found Symp 1987, 126: 82-95.
2. Lewin, G.R., Rueff, A., Mendell, L.M. et al. Peripheral and central mechanisms of NGF induced hyperalgesia. Eur J Neurosci 1994, 6: 1903-12.
3. Woolf, C.J., Safieh-Garabedian, B., Ma, Q.P., Crilly, P., Winter, J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 1994, 62: 327-31.
4. Ma, Q.P., Woolf, C.J. The progressive tactile hyperalgesia induced by peripheral inflammation is nerve growth factor dependent. Neuroreport 1997, 8: 807-10.
5. Hefti, F.F., Rosenthal, A., Walicke, P.A. et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006, 27(2): 85-91.
6. Pezet, S., McMahon, S.B. Neurotrophins: Mediators and modulators of pain. Annu Rev Neurosci 2006, 29: 507-38.
7. Mantyh, P., Tive, L., Shelton, D. Tanezumab, a humanized anti-nerve growth factor antibody for the treatment of pain. 28th Annu Sci Meet Am Pain Soc (May 7-9, San Diego) 2009, Abst 275.
8. Halvorson, K.G. et al. Therapies which attenuate mixed metastatic bone cancer pain. 11th World Congr Pain (Aug 21-26, Sydney) 2005, Abst 1076-P318.
9. Halvorson, K.G., Kubota, K., Sevcik, M.A. et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005, 65(20): 9426-35.
10. Sevcik, M.A., Ghilardi, J.R., Peters, C.M. et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005, 115(1-2): 128-41.
11. Shelton, D.L., Vergara, G., Pons, J., Ho, W.H., Stratton, J. Effect of PF04383W on post-incisional pain following IV or IP administration. Annu Meet Am Soc Anesthesiol (ASA) (Oct 18-22, Orlando) 2008, Abst A1539.
12. Shelton, D.L., Zeller, J., Ho, W.H., Pons, J., Rosenthal, A. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 2005, 116(1-2): 8-16.
13. Sabsovich, I., Wei, T., Guo, T.Z. et al. Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I. Pain 2008, 138(1): 47-60.
14. Jimenez-Andrade, J.M., Martin, C.D., Koewler, N.J. et al. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain 2007, 133(1-3): 183-96.
15. Abdiche, Y.N., Malashock, D.S., Pons, J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci. 2008, 17(8): 1326-35.
16. Shelton, D.L., Zorbas, M., Bales, R., Rogers, B., Pons, J. Preclinical safety evaluation of PF04383119 after single and multiple-dose administration in monkeys. Annu Meet Am Soc Anesthesiol (ASA) (Oct 18-22, Orlando) 2008, Abst A597.
17. Lane N. et al. RN624 (anti-NGF) improves pain and function in subjects with moderate knee osteoarthritis: A phase I study. 69th Annu Sci Meet Am Coll Rheumatol (Nov 12-17, San Diego) 2005, Abst 1205.
18. Lane, N.E., Schnitzer, T.J., Smith, M.D., Brown, M.T. Tanezumab relieves moderate to severe pain due to osteoarthritis (OA) of the knee: A phase 2 trial. 72nd Annu Sci Meet Am Coll Rheumatol (Oct 24-29, San Francisco) 2008, Abst 1989.
19. Lane, N.E., Schnitzer, M.D., Brown, M.T. Efficacy and safety of PF04383119 in treating moderate to severe pain due to osteoarthritis (OA). Annu Eur Congr Rheumatol (EULAR) (June 11-14, Paris) 2008, Abst THU0318.
20. Tive, L., Schnitzer, T.J., Katz, N. et al. Tanezumab, a humanized anti-nerve Growth factor antibody in the treatment of three chronic pain types. Pain Med (Malden) 2010, 11(2): Abst 151.
21. Katz, N., Borenstein, D., Birbara, C. et al. Tanezumab, an anti-nerve growth factor (NGF) antibody, for the treatment of chronic low back pain (CLBP) - A randomized, controlled, double-blind, phase 2 trial. 28th Annu Sci Meet Am Pain Soc (May 7-9, San Diego) 2009, Abst 268.
22. Modwin, R.M., Evans, R.J., Cossons, N. et al. Efficacy and safety of tanezumab for the treatment of interstitial cystitis. Eur Urol Suppl 2010, 9(2): Abst 639.
23. Measure exposure of tanezumab in healthy volunteers when administering the drug subcutaneously (NCT00788294). ClinicalTrials.gov Web site, April 15, 2010.
24. Study to assess changes in the number of nerves in the skin at the site where tanezumab is injected (NCT01030640). ClinicalTrials.gov Web site, April 15, 2010.
25. Hefti, F., Mokhtarani, M., Gray, M., Zhao, C., Chan, C. RN624 (anti.NGF) reduces pain and improves function in subjects with moderate to severe pain from osteoarthritis of the knee. 25th Annu Sci Meet Am Pain Soc (May 3-6, San Antonio) 2006, Abst 778.
26. A phase II study looking at moderate to severe osteoarthritis knee pain (NCT00394563). ClinicalTrials.gov Web site, April 15, 2010.
27. Schnitzer, T.J., Lane, N.E., Smith, M.D., Brown, M.T. Efficacy and safety of PF04383119 for moderate to severe pain due to osteoarthritis (OA) of the knee: A randomized trial. 12th World Congr Pain (Aug 17-22, Glasgow) 2008, Abst PT 214.
28. A phase 1/2A, single dose study of PF-04383119 in Japanese patients with moderate to severe pain from osteoarthritis of the knee (NCT00669409). ClinicatTrials.gov Web site, April 15, 2010.
29. Tanezumab in osteoarthritis of the knee (NCT00733902). ClinicalTrials.gov Web site, April 15, 2010.
30. Efficacy and safety study of tanezumab subcutaneous administration in osteoarthritis. A subcutaneous/intravenous bridging study (NCT01089725). ClinicalTrials.gov Web site, April 15, 2010.
31. Extension study of tanezumab in osteoarthritis (NCT00809783). ClinicalTrials.gov Web site, April 15, 2010.
32. Long-term study of the safety of tanezumab in arthritis patients (NCT00960804). ClinicalTrials.gov Web site, April 15, 2010.
33. Tanezumab and nerve function in arthritis patients (NCT00863772). ClinicalTrials.gov Web site, April 15, 2010.
34. Tanezumab in osteoarthritis of the hip or knee (2) (NCT00853304). ClinicalTrials.gov Web site, April 15, 2010.
35. Tanezumab in osteoarthritis of the hip or knee (NCT00985621). ClinicalTrials.gov Web site, April 15, 2010.
36. Tanezumab in osteoarthritis of the hip (NCT00744471). ClinicalTriats.gov Web site, April 15, 2010.
37. Tanezumab in osteoarthritis of the knee (2) (NCT00830063). ClinicalTrials.gov Web site, April 15, 2010.
38. A long term study of the safety of tanezumab when administered by subcutaneous injections (NCT00994890). ClinicalTrials.gov Web site, April 15, 2010.
39. Safety extension study of tanezumab when administered by subcutaneous injection to patients with osteoarthritis (NCT01127893). ClinicalTrials.gov Web site, April 15, 2010.
40. A study of tanezumab in adults with chronic low back pain (NCT00876187). ClinicalTrials.gov Web site, April 15, 2010.
41. Long term safety study of tanezumab in chronic low back pain (NCT00924664). ClinicalTrials.gov Web site, April 15, 2010.
42. A study to Investigate tanezumab in patients with interstitial cystitis/painful bladder syndrome (NCT00999518). ClinicalTrials.gov Web site, April 15, 2010.
43. A study of the analgesic (pain-relief) effects of tanezumab in adult patients with diabetic peripheral neuropathy (NCT01087203). CtinicalTrials.gov Web site, April 15, 2010.
44. Open label extension in cancer patients (NCT00830180). ClinicalTrials.gov Web site, April 15, 2010.
45. An efficacy and safety study of tanezumab for the treatment of pain associated with chronic bacterial prostatitis (NCT00926514). ClinicalTrials.gov Web site, April 15, 2010.
46. Analgesic efficacy and safety of tanezumab added on to diclofenac SR in patients with osteoarthritis of the knee or hip (NCT00864097). ClinicalTrials.gov Web site, April 15, 2010.
47. Long-term analgesic efficacy and safety of tanezumab alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDs) versus NSAIDs alone in patients with osteoarthritis of the knee or hip (NCT00809354). ClinicalTrials.gov Web site, April 15, 2010.
48. A study of tanezumab as add-on therapy to opioid medication in patients with pain due to cancer that has spread to bone (NCT00545129). ClinicalTrials.gov Web site, April 15, 2010.